Asian Journal Of Social Pharmacy

Abstract: Objective To study and analyze the status of patent protection of prostaglandin analogues for glaucoma in China. Methods Patent literatures published up to April 7, 2020 were retrieved by the keywords “PG” and “prostaglandin” on such patent information service platforms as SIPO, SooPat, and IncoPat. And then they were statistically analyzed by qualitative and quantitative means. Results and Conclusion A total of 300 patent literature related to prostaglandin analogues for glaucoma were obtained, and most of them were invention patents, including patents for composition and dosage form, indications and uses, related synthesis, the compound, and composition preparations. Prostaglandin analogues play an important role in the treatment of glaucoma. At present, China has a large number of patents applications, and the patent protection covers a wide range of technical fields, but the number of patents with valid legal status is relatively small. Therefore, China’s pharmaceutical enterprises and R&D institutions have more options in topic selection and project approval and patent protection strategies.

Key words: glaucoma, prostaglandin, patent protection